Zebrafish based assays for the assessment of cardiac, visual and gut function - potential safety screens for early drug discovery

Journal of Pharmacological and Toxicological Methods

Volumn 58, Issue 1, 2008, Pages 59-68

  Berghmans, Stéphane ^a   Butler, Paul ^b   Goldsmith, Paul ^a   Waldron, Gareth ^b   Gardner, Iain ^b   Golder, Zoe ^a   Richards, Frances M ^a   Kimber, Gillian ^a   Roach, Alan ^a   Alderton, Wendy ^a   Fleming, Angeleen ^a  

^a SUMMIT PLC   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Cardiac function assessment; Drug safety assessment; Gut motility assessment; QT prolongation; Safety pharmacology; Visual function assessment; Zebrafish methods

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ATROPINE; CHLOROQUINE; CHLORPROMAZINE; CISAPRIDE; CROMAKALIM; DIAZEPAM; ISOPRENALINE; LITHIUM; MOXIFLOXACIN; NICOTINE; NITRENDIPINE; PHENYTOIN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG UPTAKE; EXPOSURE VARIABLE; GASTROINTESTINAL TOXICITY; HEART FUNCTION; HEART RHYTHM; INTESTINE FUNCTION; MAXIMUM TOLERATED DOSE; NONHUMAN; OUTCOME ASSESSMENT; VISION; VISUAL DISORDER; ZEBRA FISH;

ANIMALS; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL TRACT; HEART; HUMANS; LARVA; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; SPECIES SPECIFICITY; TIME FACTORS; TOXICITY TESTS; VISION; ZEBRAFISH;

DANIO RERIO;

EID: 50049103885     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2008.05.130     Document Type: Article

References (70)

1. Amsterdam A., and Hopkins N. Mutagenesis strategies in zebrafish for identifying genes involved in development and disease. Trends in Genetics 22 (2006) 473-478
2. Bang P.I., Yelick P.C., Malicki J.J., and Sewell W.F. High-throughput behavioral screening method for detecting auditory response defects in zebrafish. Journal of Neuroscience Methods 118 (2002) 177-187
3. Baraban S.C., Taylor M.R., Castro P.A., and Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 131 (2005) 759-768
4. Barrett R., Chappell C., Quick M., and Fleming A. A rapid, high content, in vivo model of glucocorticoid-induced osteoporosis. Biotechnology Journal 1 (2006) 651-655
5. Bass A., Kinter L., and Williams P. Origins, practices and future of safety pharmacology. Journal of Pharmacological and Toxicological Methods 49 (2004) 145-151
6. Bass A.S., Tomaselli G., Bullingham III R., and Kinter L.B. Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices. Journal of Pharmacological and Toxicological Methods 52 (2005) 12-21
7. Berghmans S., Hunt J., Roach A., and Goldsmith P. Zebrafish offer the potential for a primary screen to identify a wide variety of potential anticonvulsants. Epilepsy Research 75 (2007) 18-28
8. Berghmans S., Jette C., Langenau D., Hsu K., Stewart R., Look T., et al. Making waves in cancer research: new models in the zebrafish. Biotechniques 39 (2005) 227-237
9. Best J.D., Berghmans S., Hunt J.J., Clarke S.C., Fleming A., Goldsmith P., et al. Non-associative learning in larval zebrafish. Neuropsychopharmacology 33 (2007) 1206-1215
10. Bilotta J., and Saszik S. The zebrafish as a model visual system. International Journal of Developmental Neuroscience 19 (2001) 621-629
11. Buchheit K.H., and Bertholet A. Inhibition of small intestine motility by cromakalim (BRL 34915). European Journal of Pharmacology 154 (1988) 335-337
12. Chouabe C., Drici M.D., Romey G., Barhanin J., and Lazdunski M. HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Molecular Pharmacology 54 (1998) 695-703
13. Clark, D.T. (1981). Visual responses in developing zebrafish (Brachydanio rerio). pp. xi, 138 leaves.
14. Claude J.R., and Claude N. Safety pharmacology: an essential interface of pharmacology and toxicology in the non-clinical assessment of new pharmaceuticals. Toxicology Letters 151 (2004) 25-28
15. Clayton N.M., and Gale J.D. 5-HT4 receptors are not involved in the control of small intestinal transit in the fasted conscious rat. Neurogastroenterology and Motility 8 (1996) 1-8
16. Coruzzi G., and Poli E. Changes in duodenal contractility induced by "calcium antagonists" with different modes of action. General Pharmacology 18 (1987) 69-74
17. De Ponti F., D'Angelo L., Frigo G.M., and Crema A. Inhibitory effects of calcium channel blockers on intestinal motility in the dog. European Journal of Pharmacology 168 (1989) 133-144
18. Fish F.A., Prakash C., and Roden D.M. Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators. Circulation 82 (1990) 1362-1369
19. Fleming A., Sato M., and Goldsmith P. High-throughput in vivo screening for bone anabolic compounds with zebrafish. Journal of Biomolecular Screening 10 (2005) 823-831
20. Fox D.A., Rubinstein S.D., and Hsu P. Developmental lead exposure inhibits adult rat retinal, but not kidney, Na+,K(+)-ATPase. Toxicology and Applied Pharmacology 109 (1991) 482-493
21. Giacomini N.J., Rose B., Kobayashi K., and Guo S. Antipsychotics produce locomotor impairment in larval zebrafish. Neurotoxicology and Teratology 28 (2006) 245-250
22. Goldsmith P. Zebrafish as a pharmacological tool: the how, why and when. Current Opinion in Pharmacology 4 (2004) 504-512
23. Goldsmith P., Golder Z., Hunt J., Berghmans S., Jones D., Stables J.P., et al. GBR12909 possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy but cardiac ion channel effects limit its clinical utility. Pharmacology 79 (2007) 250-258
24. Grunwald D.J., and Eisen J.S. Headwaters of the zebrafish - emergence of a new model vertebrate. Nature Reviews. Genetics 3 (2002) 717-724
25. Hadjikoutis S., Morgan J.E., Wild J.M., and Smith P.E. Ocular complications of neurological therapy. European Journal of Neurology 12 (2005) 499-507
26. Hicks C., Sorocco D., and Levin M. Automated analysis of behavior: a computer-controlled system for drug screening and the investigation of learning. Journal of Neurobiology 66 (2006) 977-990
27. Holmberg A., Olsson C., and Holmgren S. The effects of endogenous and exogenous nitric oxide on gut motility in zebrafish Danio rerio embryos and larvae. Journal of Experimental Biology 209 (2006) 2472-2479
28. Holmberg A., Schwerte T., Fritsche R., Pelster B., and Holmgren S. Ontogeny of intestinal motility in correlation to neuronal development in zebrafish embryos and larvae. Journal of Fish Biology 63 (2003) 318-331
29. Holmberg A., Schwerte T., Pelster B., and Holmgren S. Ontogeny of the gut motility control system in zebrafish Danio rerio embryos and larvae. Journal of Experimental Biology 207 (2004) 4085-4094
30. http://www.sanger.ac.uk/Projects/D_rerio/.
31. Huuskonen H. New models and molecular markers in evaluation of developmental toxicity. Toxicology and Applied Pharmacology 207 (2005) 495-500
32. Jaanus S.D. Ocular side effects of selected systemic drugs. Optometry Clinics 2 (1992) 73-96
33. Kalvass J.C., and Maurer T.S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharmaceutics & Drug Disposition 23 (2002) 327-338
34. Keller T.H., Pichota A., and Yin Z. A practical view of 'druggability'. Current Opinion in Chemical Biology 10 (2006) 357-361
35. Kim K.S., and Kim E.J. The phenothiazine drugs inhibit hERG potassium channels. Drug and Chemical Toxicology 28 (2005) 303-313
36. Kimmel C.B., Ballard W.W., Kimmel S.R., Ullmann B., and Schilling T.F. Stages of embryonic development of the zebrafish. Developmental Dynamics 203 (1995) 253-310
37. Lam S.H., Wu Y.L., Vega V.B., Miller L.D., Spitsbergen J., Tong Y., et al. Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nature Biotechnology 24 (2006) 73-75
38. Langheinrich U., Vacun G., and Wagner T. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicology and Applied Pharmacology 193 (2003) 370-382
39. Lawrence C.L., Pollard C.E., Hammond T.G., and Valentin J.P. Nonclinical proarrhythmia models: predicting Torsades de Pointes. Journal of Pharmacological and Toxicological Methods 52 (2005) 46-59
40. Lee S.Y., Choi S.Y., Youm J.B., Ho W.K., Earm Y.E., Lee C.O., et al. Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine. Journal of Cardiovascular Pharmacology 43 (2004) 706-714
41. Maurer T.S., Debartolo D.B., Tess D.A., and Scott D.O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metabolism and Disposition 33 (2005) 175-181
42. Milan D.J., Jones I.L., Ellinor P.T., and MacRae C.A. In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation. American Journal of Physiology. Heart and Circulatory Physiology 291 (2006) H269-H273
43. Milan D.J., Peterson T.A., Ruskin J.N., Peterson R.T., and MacRae C.A. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 107 (2003) 1355-1358
44. Mohideen M.A., Beckwith L.G., Tsao-Wu G.S., Moore J.L., Wong A.C., Chinoy M.R., et al. Histology-based screen for zebrafish mutants with abnormal cell differentiation. Developmental Dynamics 228 (2003) 414-423
45. Murphey R.D., Stern H.M., Straub C.T., and Zon L.I. A chemical genetic screen for cell cycle inhibitors in zebrafish embryos. Chem Biol Drug Des 68 (2006) 213-219
46. Ninkovic J., and Bally-Cuif L. The zebrafish as a model system for assessing the reinforcing properties of drugs of abuse. Methods 39 (2006) 262-274
47. Parng C., Roy N.M., Ton C., Lin Y., and McGrath P. Neurotoxicity assessment using zebrafish. Journal of Pharmacological and Toxicological Methods 55 (2007) 103-112
48. Pickart M.A., Klee E.W., Nielsen A.L., Sivasubbu S., Mendenhall E.M., Bill B.R., et al. Genome-wide reverse genetics framework to identify novel functions of the vertebrate secretome. PLoS ONE 1 (2006) e104
49. Postlethwait J.H., Woods I.G., Ngo-Hazelett P., Yan Y.L., Kelly P.D., Chu F., et al. Zebrafish comparative genomics and the origins of vertebrate chromosomes. Genome Research 10 (2000) 1890-1902
50. Rampe D., Roy M.L., Dennis A., and Brown A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Letters 417 (1997) 28-32
51. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
52. Roeser T., and Baier H. Visuomotor behaviors in larval zebrafish after GFP-guided laser ablation of the optic tectum. Journal of Neuroscience 23 (2003) 3726-3734
53. Rombough P. Gills are needed for ionoregulation before they are needed for O(2) uptake in developing zebrafish, Danio rerio. Journal of Experimental Biology 205 (2002) 1787-1794
54. Rubinstein A.L. Zebrafish assays for drug toxicity screening. Expert Opinion on Drug Metabolism and Toxicology 2 (2006) 231-240
55. Santaella R.M., and Fraunfelder F.W. Ocular adverse effects associated with systemic medications: recognition and management. Drugs 67 (2007) 75-93
56. Schneider J., Hauser R., Andreas J.O., Linz K., and Jahnel U. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. European Journal of Pharmacology 512 (2005) 53-60
57. Shin J.T., and Fishman M.C. From zebrafish to human: modular medical models. Annual Review in Genomics and Human Genetics 3 (2002) 311-340
58. Soules K.A., and Link B.A. Morphogenesis of the anterior segment in the zebrafish eye. BMC Developmental Biology 5 (2005) 12
59. Sriram K., Schumer W., Ehrenpreis S., Comaty J.E., and Scheller J. Phenothiazine effect on gastrointestinal tract function. American Journal of Surgery 137 (1979) 87-91
60. Suter W. Predictive value of in vitro safety studies. Current Opinion in Chemical Biology 10 (2006) 362-366
61. Thollander M., Svensson T.H., and Hellstrom P.M. Beta-adrenoceptors regulate myoelectric activity in the small intestine of rats: stimulation by beta 2 and inhibition by beta 3 subtypes. Neurogastroenterology and Motility 8 (1996) 143-151
62. Vihtelic T.S., Doro C.J., and Hyde D.R. Cloning and characterization of six zebrafish photoreceptor opsin cDNAs and immunolocalization of their corresponding proteins. Visual Neuroscience 16 (1999) 571-585
63. von Hofsten J., and Olsson P.E. Zebrafish sex determination and differentiation: involvement of FTZ-F1 genes. Reproductive Biology and Endocrinology 3 (2005) 63
64. Walker B.D., Singleton C.B., Bursill J.A., Wyse K.R., Valenzuela S.M., Qiu M.R., et al. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. British Journal of Pharmacology 128 (1999) 444-450
65. Wang C., Tian J., Liang P., and Sun F. Diazepam-induced changes of optokinetic nystagmus fast phase. Experimental Brain Research 167 (2005) 446-450
66. Westerfield M. The zebrafish book: A guide for the laboratory use of zebrafish (danio rerio) (1995), M. Westerfield, Eugene, Or.
67. Xiong Y.Q., and Li B.H. [Inhibitory action of chlorpromazine on intestinal movement in mice and its antagonistic agents]. Zhongguo Yaoli Xuebao 15 (1994) 235-239
68. Zhdanova I.V., Wang S.Y., Leclair O.U., and Danilova N.P. Melatonin promotes sleep-like state in zebrafish. Brain Research 903 (2001) 263-268
69. Zingler V.C., Denecke K., Jahn K., von Meyer L., Krafczyk S., Krams M., et al. The effect of nicotine on perceptual, ocular motor, postural, and vegetative functions at rest and in motion. Journal of Neurology 254 (2007) 1689-1697
70. Zon L.I. Zebrafish: a new model for human disease. Genome Research (1999) 99-100